Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)

NCT02016183 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3222

Last updated 2018-11-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term use of candesartan cilexetil / hydrochlorothiazide combination tablets (ECARD) Combination Tablets LD\&HD in hypertensive patients in the routine clinical setting

Conditions

Interventions

DRUG

Candesartan cilexetil / hydrochlorothiazide

Candesartan cilexetil / hydrochlorothiazide combination tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-01
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02016183 on ClinicalTrials.gov